{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:00:03Z","timestamp":1791968403848,"version":"4.3.4"},"reference-count":132,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Myasthenia gravis (MG) is a chronic autoimmune disease for which multiple immunomodulatory therapies are available. Nevertheless, MG has a significant impact on patient quality of life. In recent years, experts\u2019 main efforts have focused on optimizing treatment strategies, since disease burden is considerably affected by their safety and tolerability profiles, especially in patients with refractory phenotypes. This article aims to offer neurologists caring for MG patients an overview of the most innovative targeted drugs specifically designed for this disease and summarizes the recent literature and more recent evidence on agents targeting B cells and plasmablasts, complement inhibitors, and neonatal fragment crystallizable receptor (FcRn) antagonists. Positive clinical trial results have been reported, and other studies are ongoing. Finally, we briefly discuss how the introduction of these novel targeted immunological therapies in a changing management paradigm would affect not only clinical outcomes, disease burden, safety, and tolerability, but also health spending in a condition that is increasingly managed based on a patient-centred model.<\/jats:p>","DOI":"10.3390\/jcm11216394","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T07:26:50Z","timestamp":1667114810000},"page":"6394","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["New Targeted Agents in Myasthenia Gravis and Future Therapeutic Strategies"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5624-638X","authenticated-orcid":false,"given":"Daniel","family":"S\u00e1nchez-Tejerina","sequence":"first","affiliation":[{"name":"Clinic of Neuromuscular Disorders and Rare Diseases, Neurology Department, Hospital Universitari Vall d\u2019Hebron, Vall d\u2019Hebron Research Institute, European Reference Network for Neuromuscular and Rare Diseases EURO-NMD, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3400-1434","authenticated-orcid":false,"given":"Javier","family":"Sotoca","sequence":"additional","affiliation":[{"name":"Clinic of Neuromuscular Disorders and Rare Diseases, Neurology Department, Hospital Universitari Vall d\u2019Hebron, Vall d\u2019Hebron Research Institute, European Reference Network for Neuromuscular and Rare Diseases EURO-NMD, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-6157","authenticated-orcid":false,"given":"Arnau","family":"Llaurado","sequence":"additional","affiliation":[{"name":"Clinic of Neuromuscular Disorders and Rare Diseases, Neurology Department, Hospital Universitari Vall d\u2019Hebron, Vall d\u2019Hebron Research Institute, European Reference Network for Neuromuscular and Rare Diseases EURO-NMD, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"L\u00f3pez-Diego","sequence":"additional","affiliation":[{"name":"Clinic of Neuromuscular Disorders and Rare Diseases, Neurology Department, Hospital Universitari Vall d\u2019Hebron, Vall d\u2019Hebron Research Institute, European Reference Network for Neuromuscular and Rare Diseases EURO-NMD, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Juntas-Morales","sequence":"additional","affiliation":[{"name":"Clinic of Neuromuscular Disorders and Rare Diseases, Neurology Department, Hospital Universitari Vall d\u2019Hebron, Vall d\u2019Hebron Research Institute, European Reference Network for Neuromuscular and Rare Diseases EURO-NMD, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Salvado","sequence":"additional","affiliation":[{"name":"Clinic of Neuromuscular Disorders and Rare Diseases, Neurology Department, Hospital Universitari Vall d\u2019Hebron, Vall d\u2019Hebron Research Institute, European Reference Network for Neuromuscular and Rare Diseases EURO-NMD, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia Gravis: Recommendations for Clinical Research Standards","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"ref_3","first-page":"e9184","article-title":"A Review of Psychiatric Comorbidity in Myasthenia Gravis","volume":"12","author":"Law","year":"2020","journal-title":"Cureus"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/mus.26695","article-title":"Cross-Sectional Analysis of the Myasthenia Gravis Patient Registry: Disability and Treatment","volume":"60","author":"Cutter","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Bacci, E.D., Coyne, K.S., Poon, J.L., Harris, L., and Boscoe, A.N. (2019). Understanding Side Effects of Therapy for Myasthenia Gravis and Their Impact on Daily Life. BMC Neurol., 19.","DOI":"10.1186\/s12883-019-1573-2"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e048198","DOI":"10.1136\/bmjopen-2020-048198","article-title":"Patient-Reportedimpact of Myasthenia Gravis in the Real World: Protocol for a Digital Observational Study (MyRealWorld MG)","volume":"11","author":"Claeys","year":"2021","journal-title":"BMJ Open"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","article-title":"The Lived Experience of Myasthenia Gravis: A Patient-Led Analysis","volume":"10","author":"Law","year":"2021","journal-title":"Neurol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"120268","DOI":"10.1016\/j.jns.2022.120268","article-title":"The Humanistic Burden of Myasthenia Gravis: A Systematic Literature Review","volume":"437","author":"Gelinas","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3109\/00207454.2015.1038712","article-title":"Quality of Life in 188 Patients with Myasthenia Gravis in China","volume":"126","author":"Yang","year":"2016","journal-title":"Int. J. Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","article-title":"Clinical Features and Impact of Myasthenia Gravis Disease in Australian Patients","volume":"22","author":"Blum","year":"2015","journal-title":"J. Clin. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1756286419832242","DOI":"10.1177\/1756286419832242","article-title":"Understanding the Burden of Refractory Myasthenia Gravis","volume":"12","author":"Hagenacker","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3988\/jcn.2019.15.3.376","article-title":"Examining the Impact of Refractory Myasthenia Gravis on Healthcare Resource Utilization in the United States: Analysis of a Myasthenia Gravis Foundation of America Patient Registry Sample","volume":"15","author":"Xin","year":"2019","journal-title":"J. Clin. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1007\/s10072-022-06102-y","article-title":"HLA-DQB1*05:02, *05:03, and *03:01 Alleles as Risk Factors for Myasthenia Gravis in a Spanish Cohort","volume":"43","author":"Salvado","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in Myasthenia Gravis in the Era of Biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1749-6632.2012.06840.x","article-title":"Functional Defect in Regulatory T Cells in Myasthenia Gravis","volume":"1274","author":"Thiruppathi","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T Cells in Autoimmune Disease","volume":"19","author":"Hafler","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/nyas.13560","article-title":"Pathophysiological Mechanisms of Autoimmunity","volume":"1413","author":"Sudres","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia Gravis: A Comprehensive Review of Immune Dysregulation and Etiological Mechanisms","volume":"52","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle Autoantibodies in Myasthenia Gravis: Beyond Diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia Gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 Antibodies to Acetylcholine Receptors in \u201cseronegative\u201d Myasthenia Gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and Pathogenic Relevance of Antibodies to Clustered Acetylcholine Receptor in Ocular and Generalized Myasthenia Gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00401-020-02147-5","article-title":"Complement Deposition at the Neuromuscular Junction in Seronegative Myasthenia Gravis","volume":"139","author":"Hoffmann","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Koneczny, I., and Herbst, R. (2019). Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture. Cells, 8.","DOI":"10.3390\/cells8070671"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fnmol.2020.00086","article-title":"Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability","volume":"13","author":"Takamori","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Koneczny, I., Cossins, J., Waters, P., Beeson, D., and Vincent, A. (2013). MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080695"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 Autoantibodies against Muscle-Specific Kinase Undergo Fab-Arm Exchange in Myasthenia Gravis Patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J. Autoimmun."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Dalakas, M.C. (2022). IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies. Neurol. Neuroimmunol. Neuroinflamm., 9.","DOI":"10.1212\/NXI.0000000000001116"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to Low-Density Lipoprotein Receptor-Related Protein 4 in Myasthenia Gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B Cells in the Pathophysiology of Myasthenia Gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B Cells and Plasma Cells in Autoimmune Diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-020-00704-w","article-title":"Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis","volume":"34","author":"Sellebjerg","year":"2020","journal-title":"CNS Drugs"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B Cell Depletion Therapies in Autoimmune Disease: Advances and Mechanistic Insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncpneuro0901","article-title":"B Cells as Therapeutic Targets in Autoimmune Neurological Disorders","volume":"4","author":"Dalakas","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-Cell Subpopulations in Humans and Their Differential Susceptibility to Depletion with Anti-CD20 Monoclonal Antibodies","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.25597","article-title":"Rituximab Treatment of Myasthenia Gravis: A Systematic Review","volume":"56","author":"Tandan","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in Refractory Myasthenia Gravis: Extended Prospective Study Results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","article-title":"High Efficacy of Rituximab for Myasthenia Gravis: A Comprehensive Nationwide Study in Austria","volume":"266","author":"Topakian","year":"2019","journal-title":"J. Neurol."},{"key":"ref_40","first-page":"S139","article-title":"Rituximab in Patients with Moderate to Severe Myasthenia Gravis: A Subgroup Analysis of the BeatMG Study. AANEM Annual Meeting Abstract Guide Austin, TX, October 16\u201319, 2019","volume":"60","author":"Nowak","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/ene.14391","article-title":"Efficacy and Safety of Rituximab in Myasthenia Gravis: A French Multicentre Real-Life Study","volume":"27","author":"Noury","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","article-title":"Comparison between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis","volume":"77","author":"Brauner","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1756286419871187","DOI":"10.1177\/1756286419871187","article-title":"Repeated Low-Dose Rituximab Treatment Based on the Assessment of Circulating B Cells in Patients with Refractory Myasthenia Gravis","volume":"12","author":"Choi","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mus.26790","article-title":"Low-Dose Rituximab Every 6 Months for the Treatment of Acetylcholine Receptor\u2013Positive Refractory Generalized Myasthenia Gravis","volume":"61","author":"Lu","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jocn.2020.11.043","article-title":"Efficacy and Safety of Different Dosages of Rituximab for Refractory Generalized AChR Myasthenia Gravis: A Meta-Analysis","volume":"85","author":"Li","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","article-title":"Rituximab as Treatment for Anti-MuSK Myasthenia Gravis","volume":"89","author":"Hehir","year":"2017","journal-title":"Neurology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","article-title":"Long-Lasting Rituximab-Induced Reduction of Specific\u2014But Not Total\u2014IgG4 in MuSK-Positive Myasthenia Gravis","volume":"11","author":"Marino","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/acn3.564","article-title":"The Impact of Rituximab Infusion Protocol on the Long-Term Outcome in Anti-MuSK Myasthenia Gravis","volume":"5","author":"Querol","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/nyas.13535","article-title":"Mechanisms Underlying B Cell Immune Dysregulation and Autoantibody Production in MuSK Myasthenia Gravis","volume":"1412","author":"Stathopoulos","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study","volume":"98","author":"Nowak","year":"2022","journal-title":"Neurology"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Piehl, F., Eriksson-Dufva, A., Budzianowska, A., Feresiadou, A., Hansson, W., Hietala, M.A., H\u00e5kansson, I., Johansson, R., Jons, D., and Kmezic, I. (2022). Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. JAMA Neurol.","DOI":"10.1001\/jamaneurol.2022.2887"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"736190","DOI":"10.3389\/fneur.2021.736190","article-title":"Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.nmd.2022.06.006","article-title":"Rituximab in Myasthenia Gravis: Efficacy, Associated Infections and Risk of Induced Hypogammaglobulinemia","volume":"32","author":"Moga","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","article-title":"Rituximab in Neurological Disease: Principles, Evidence and Practice","volume":"19","author":"Whittam","year":"2019","journal-title":"Pract. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s13311-022-01196-w","article-title":"Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases","volume":"19","author":"Stathopoulos","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","article-title":"Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status","volume":"79","author":"Beecher","year":"2019","journal-title":"Drugs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1002\/mus.26707","article-title":"Refractory Myasthenia Gravis Successfully Treated with Ofatumumab","volume":"60","author":"Waters","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Chen, D., Gallagher, S., Monson, N.L., Herbst, R., and Wang, Y. (2016). Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J. Clin. Med., 5.","DOI":"10.3390\/jcm5120107"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","article-title":"Inebilizumab: First Approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"ref_60","unstructured":"(2022, August 31). A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study With Open-Label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct04524273."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40259-020-00443-w","article-title":"Monoclonal Antibody-Based Therapies for Myasthenia Gravis","volume":"34","author":"Alabbad","year":"2020","journal-title":"BioDrugs"},{"key":"ref_62","unstructured":"(2022, August 31). A Multi-Centre, Randomized, Double- Blind, Placebo-Controlled, Parallel Group Study to Preliminarily Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of CFZ533 in Patients With Moderate to Severe Myasthenia Gravis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/nct02565576."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Field-Smith, A., Morgan, G.J., and Davies, F.E. (2006). Bortezomib (Velcadetrade Mark) in the Treatment of Multiple Myeloma. Ther. Clin. Risk Manag., 2.","DOI":"10.2147\/tcrm.2006.2.3.271"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e024523","DOI":"10.1136\/bmjopen-2018-024523","article-title":"Bortezomib in Antibody-Mediated Autoimmune Diseases (TAVAB): Study Protocol for a Unicentric, Non-Randomised, Non-Placebo Controlled Trial","volume":"9","author":"Kohler","year":"2019","journal-title":"BMJ Open"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.neuro.2014.02.001","article-title":"Neurotoxicity Induced by Antineoplastic Proteasome Inhibitors","volume":"43","author":"Bruna","year":"2014","journal-title":"Neurotoxicology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/cge.13015","article-title":"The Investigation of Genetic and Clinical Features in Chinese Patients with Juvenile Amyotrophic Lateral Sclerosis","volume":"92","author":"Liu","year":"2017","journal-title":"Clin. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/intimm\/dxg111","article-title":"Death of T Cell Precursors in the Human Thymus: A Role for CD38","volume":"15","author":"Tenca","year":"2003","journal-title":"Int. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"851864","DOI":"10.3389\/fonc.2022.851864","article-title":"Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma","volume":"12","author":"Bonello","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_70","unstructured":"(2022, August 31). A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct04159805."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/ene.15266","article-title":"Daratumumab for Treatment-Refractory Antibody-Mediated Diseases in Neurology","volume":"29","author":"Scheibe","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaut.2010.12.001","article-title":"Blocking of IL-6 Suppresses Experimental Autoimmune Myasthenia Gravis","volume":"36","author":"Aricha","year":"2011","journal-title":"J. Autoimmun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","article-title":"Beneficial Effect of Tocilizumab in Myasthenia Gravis Refractory to Rituximab","volume":"27","author":"Jonsson","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/mus.26918","article-title":"COVID-19 in Patients with Myasthenia Gravis","volume":"62","author":"Anand","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_75","unstructured":"(2022, August 31). A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct05067348."},{"key":"ref_76","unstructured":"(2022, September 04). A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct04963270."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00296-020-04587-4","article-title":"Adalimumab-Induced Myasthenia Gravis: Case-Based Review","volume":"40","author":"Pelechas","year":"2020","journal-title":"Rheumatol. Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.nmd.2020.01.001","article-title":"Myasthenia Gravis after Etanercept and Ustekinumab Treatment for Psoriatic Arthritis: A Case Report","volume":"30","author":"Nicocia","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.coi.2010.09.010","article-title":"Targeting BAFF in Autoimmunity","volume":"22","author":"Davidson","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mus.25162","article-title":"B-Cell\u2013Activating Factor Is Elevated in Serum of Patients with Myasthenia Gravis","volume":"54","author":"Kang","year":"2016","journal-title":"Muscle Nerve"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","article-title":"Randomized Study of Adjunctive Belimumab in Participants with Generalized Myasthenia Gravis","volume":"90","author":"Hewett","year":"2018","journal-title":"Neurology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton\u2019s Tyrosine Kinase (Btk): Function, Regulation, and Transformation with Special Emphasis on the PH Domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects","volume":"9","author":"Zain","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","article-title":"Safety and Efficacy of Tolebrutinib, an Oral Brain-Penetrant BTK Inhibitor, in Relapsing Multiple Sclerosis: A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"20","author":"Reich","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_85","unstructured":"(2022, August 31). A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Tolebrutinib (SAR442168) in Adults With Generalized Myasthenia Gravis (MG), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct05132569."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005072-197803000-00008","article-title":"Ultrastructural Localization of Immune Complexes (IgG and C3) at the End-Plate in Experimental Autoimmune Myasthenia Gravis","volume":"37","author":"Sahashi","year":"1978","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/nyas.13555","article-title":"Acetylcholine Receptor Antibody-Mediated Animal Models of Myasthenia Gravis and the Role of Complement","volume":"1413","author":"Kusner","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia Gravis: Quantitative Immunocytochemical Analysis of Inflammatory Cells and Detection of Complement Membrane Attack Complex at the End-Plate in 30 Patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0165-5728(96)00133-6","article-title":"Increased in Vitro Uptake of the Complement C3b in the Serum of Patients with Guillain-Barr\u00e9 Syndrome, Myasthenia Gravis and Dermatomyositis","volume":"71","author":"Basta","year":"1996","journal-title":"J. Neuroimmunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.08.002","article-title":"The Role of Complement in Myasthenia Gravis: Serological Evidence of Complement Consumption in Vivo","volume":"158","author":"Romi","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJM197701202960301","article-title":"Myasthenia Gravis. Study of Humoral Immune Mechanisms by Passive Transfer to Mice","volume":"296","author":"Toyka","year":"1977","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0046-8177(78)80135-X","article-title":"The Immunopathology of Myasthenia Gravis","volume":"9","author":"Lennon","year":"1978","journal-title":"Hum. Pathol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and Efficacy of Eculizumab in Anti-Acetylcholine Receptor Antibody-Positive Refractory Generalised Myasthenia Gravis (REGAIN): A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"556104","DOI":"10.3389\/fneur.2020.556104","article-title":"Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study","volume":"11","author":"Nowak","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/1744666X.2022.2082946","article-title":"Role of Complement, Anti-Complement Therapeutics, and Other Targeted Immunotherapies in Myasthenia Gravis","volume":"18","author":"Dalakas","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Sheridan, D., Yu, Z.X., Zhang, Y., Patel, R., Sun, F., Lasaro, M.A., Bouchard, K., Andrien, B., Marozsan, A., and Wang, Y. (2018). Design and Preclinical Characterization of ALXN1210: A Novel Anti-C5 Antibody with Extended Duration of Action. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195909"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical Effects of the Self-Administered Subcutaneous Complement Inhibitor Zilucoplan in Patients with Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_101","unstructured":"(2022, August 31). A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct04115293."},{"key":"ref_102","unstructured":"Club, B., Business, F.A.Q., Bureau, G.D., and Investigate, T.V. (2022, September 04). UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results|UCB. Available online: https:\/\/www.14news.com\/prnewswire\/2022\/02\/04\/ucb-announces-positive-data-myasthenia-gravis-with-zilucoplan-phase-3-study-results\/?outputType=amp."},{"key":"ref_103","first-page":"1","article-title":"Boosting Therapeutic Potency of Antibodies by Taming Fc Domain Functions","volume":"51","author":"Kang","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc Receptor in Human Immunity: Function and Role in Therapeutic Intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00018-010-0318-6","article-title":"The Neonatal Fc Receptor as Therapeutic Target in IgG-Mediated Autoimmune Diseases","volume":"67","author":"Sesarman","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/mus.26919","article-title":"Update on Immune-Mediated Therapies for Myasthenia Gravis","volume":"62","author":"Habib","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fimmu.2020.00240","article-title":"New Approaches to Targeting B Cells for Myasthenia Gravis Therapy","volume":"11","author":"Huda","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc Receptor Antagonist Efgartigimod Safely and Sustainably Reduces IgGs in Humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, Efficacy, and Tolerability of Efgartigimod in Patients with Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_111","unstructured":"(2022, August 31). Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients with Generalized Myasthenia Gravis (ADAPTsc), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct04735432."},{"key":"ref_112","unstructured":"(2022, August 31). Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients with Generalized Myasthenia Gravis (ADAPTsc+), Available online: https:\/\/clinicaltrials.gov\/ct2\/Show\/nct04818671."},{"key":"ref_113","unstructured":"(2022, August 31). FDA Approves New Treatment for Myasthenia Gravis, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-myasthenia-gravis."},{"key":"ref_114","unstructured":"(2022, September 04). European Medicines Agency Authorization for Vyvgart (Efgartigimod) in Myasthenia Gravis. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/epar\/vyvgart#authorisation-details-section."},{"key":"ref_115","unstructured":"(2022, August 31). Efgartigimod Expanded Access for Generalized Myasthenia Gravis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct04777734."},{"key":"ref_116","first-page":"1111","article-title":"Generation and Characterization of a High Affinity Anti-Human FcRn Antibody, Rozanolixizumab, and the Effects of Different Molecular Formats on the Reduction of Plasma IgG Concentration","volume":"10","author":"Smith","year":"2018","journal-title":"MAbs"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial","volume":"96","author":"Bril","year":"2021","journal-title":"Neurology"},{"key":"ref_118","unstructured":"(2022, August 31). An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants with Generalized Myasthenia Gravis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct04650854."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cpt.1276","article-title":"M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study","volume":"105","author":"Ling","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1212\/WNL.96.15_supplement.2157","article-title":"Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis","volume":"96","author":"Guptill","year":"2021","journal-title":"Neurol."},{"key":"ref_121","unstructured":"(2022, August 31). A Study of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct04951622."},{"key":"ref_122","unstructured":"(2022, August 31). Post-Trial Access for Nipocalimab in Participants with Warm Autoimmune Hemolytic Anemia (WAIHA), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct05221619."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"102366","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-Generation Fc Receptor\u2013Targeting Biologics for Autoimmune Diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","article-title":"Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study","volume":"11","author":"Yan","year":"2022","journal-title":"Neurol. Ther."},{"key":"ref_125","unstructured":"(2022, August 31). Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct05403541."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"eaax9586","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in Humans Reduces Circulating IgG Levels and Inhibits IgG Immune Complex-Mediated Immune Responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_127","unstructured":"(2022, August 31). A Safety Study of SYNT001 in Subjects with Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct03075878."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1016\/j.jid.2021.04.031","article-title":"Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus","volume":"141","author":"Werth","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_129","unstructured":"(2022, August 31). Affibody Announces Termination of ABY-039 (FcRn) Program. Available online: https:\/\/www.affibody.se\/affibody-announces-termination-of-aby-039-fcrn-program\/#:~:text=aby-039%20is%20a%20bivalent%20antibody-mimetic%20that%20targets%20the,in%20patients%20with%20myasthenia%20gravis%20in%20Phase%203."},{"key":"ref_130","unstructured":"(2022, August 31). A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/nct03502954."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"17110","DOI":"10.1073\/pnas.1417717111","article-title":"An Engineered Affibody Molecule with PH-Dependent Binding to FcRN Mediates Extended Circulatory Half-Life of a Fusion Protein","volume":"111","author":"Seijsing","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fimmu.2020.00213","article-title":"Circulating MiRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine","volume":"11","author":"Sabre","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/21\/6394\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:05:23Z","timestamp":1760144723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/21\/6394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":132,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jcm11216394"],"URL":"https:\/\/doi.org\/10.3390\/jcm11216394","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}